Browsing Tag
CEPHEUS study
1 post
Johnson & Johnson’s DARZALEX FASPRO shows 95% survival at 4 years in multiple myeloma
DARZALEX FASPRO shows 95% four-year PFS and deep MRD responses in NDMM, raising its profile as a foundational frontline therapy. Read the full trial analysis.